Cirrhotic cardiomyopathy

Definition

Impaired cardiac functions without any organic cardiac disorder pertaining to diminished cardiac contractility when stimulated (physiological / pharmacological) and adapted relaxation during diastole with electrophysiological abnormalities in patients with cirrhosis. (Naqvi, et al, 2017)

Pathogenesis

CCM is characterized by sequential cardiac alterations responsible for its signature clinical implications. Following pathogenic mechanisms have been suggested to various components CCM. The salient components are depicted in (Figure 3). (Naqvi, et al, 2017)

Figure (3): Salient Components of Cirrhotic Cardiomyopathy.

( Naqvi, et al, 2017)
Systolic dysfunction

The data on cirrhotics (both animals and humans) evidences that systolic functions remain normal or even above normal at rest. The underlying systolic dysfunction becomes unmasked whenever there is physiologic (exercise) or pharmacologic (dobutamine infusion) stimulus. Blunted cardiac responsiveness to volume, postural changes, exercise or pharmacological stimulus has been recognized in cirrhotics. (Ruiz-del-Arbol, et al, 2013)

Physiologic stress:

The postural changes and exercise produce cardiac dysfunction among cirrhotics. When cirrhotic patients were kept standing for 5 minutes, in spite of increased HR, LV end systolic volume, cardiac index and peripheral systemic resistance decrease. Exercise in cirrhotics when compared with normal subjects has shown abnormal LV response (diminished increase in CO and ejection fraction). Patient with cirrhosis during exercise have shown unaffected cardiac index and ventricular filling pressure. (Naqvi, et al, 2017)

Non invasive assessment of ventricular contractile performance in cirrhotics at rest and during exercise can be done by measuring systolic time interval. It is assessed from concurrent tracings of carotid artery pulse, phonocardiogram and electrocardiogram. Increased systolic time interval prolongs total electromechanical systole in cirrhotics. Impaired adrenergic drive causes electromechanical delay thus increasing systolic time. (Naqvi, et al, 2017)

Effect of ascites:

The effect of ascites on cardiac dysfunction has been evaluated in various studies. Pozzi et al, 1997, showed that ascites and therapeutic paracentesis do not affect cardiac dysfunction. Wong et al, 1999, have shown end systolic volume increase due to sodium retention causing compromised cardiac contractility even before
ascites ensues. The effect becomes more important when ascites develop despite reduction of both pre and after load. (Naqvi, et al, 2017)

**Pharmacologic stress:**

Blunted cardiac response to various pharmacologic agents has been reported in cirrhotic patients. Epstein M et al. showed failure in increasing cardiac output in cirrhotics when angiotensin II was infused despite increased Pulmonary Wedge Capillary Pressure (PWCP) and normalization of SVR. Terlipressin infusion also has the same effects in patients with cirrhosis. Above studies concluded that if afterload normalizes, it may help in detection of LV dysfunction. Moreover, dobutamine (β1-adrenergic receptor agonist) in cirrhotics showed only a small rise in stroke volume (negative inotropism). Comparatively, more amount of isoproterenol is required to enhance heart rate in cirrhotics versus healthy controls (negative chronotropism). (Krag, et al, 2010)

**Diastolic dysfunction**

The diastolic dysfunction even heralds systolic dysfunction in cirrhosis. There is defective ventricular relaxation (premature passive (E) and late (A) components) during ventricular filling phase, which subsequently increases atrial pressure and isovolumetric relaxation time. (Pall, et al, 2014)

**Impaired myocardial relaxation:**

Defective calcium exchange through the sarcoplasmic reticulum is linked with impaired myocardial relaxation explains diastolic dysfunction. The elasticity of relaxed striated muscle is dependent on titin which determines diastolic stiffness. Myocardial extracellular matrix is also affected with alteration in diastolic function. Experimental models of Bile Duct Ligated Animals (BDL), show decreased phosphorylation of titin increasing passive tension. Histopathological evidence of diastolic dysfunction has shown interstitial and cardiomyocyte fibrosis along with impair
pigmentation and myocyte vacuolization. Chances of supraventricular arrhythmias like atrial fibrillation increase by augmented atrial volume consequent to impaired ventricular filling. (Chayanupatkul & Liangpunsakul, 2014)

**Myocardial hypertrophy and myocardial fibrosis:**

High salt intake among animals has shown concentric LV hypertrophy related to excessive production of aldosterone. LV hypertrophy in cirrhotics is mainly responsible for diastolic dysfunction. Among structural changes thickness of heart walls has been associated with cirrhosis of liver. Pathogenesis of myocardial fibrosis and aldosterone is linked for stimulating pro inflammatory cytokines like transforming growth factor β (TGF β). Patients having ascites (decompensated cirrhosis) with raised plasma epinephrine and Plasma Renin Activity (PRA) showed more LV hypertrophy than patients without ascites having normal PRA. (Wronski, et al, 2015)

**Echocardiographic parameters:**

The diastolic dysfunctions can be determined both by invasive (measuring pulmonary capillary wedge pressure plus end diastolic pressure) and non invasive (echocardiography) methods. Reduced SVR and central hypovolemic state in CCM explains increased cardiopulmonary pressure with normal mean left atrial or PCWP. Salient echocardiographic assessments in CCM includes left atrial dilatation with raised left atrial volume, increased LV diameter without an increase in LV volume and thickness of posterior wall of LV and inter cardiac septum. Increased Isovolumic Relaxation Time (IVRT), decreased peak E velocity (early rapid filling phase), prolong Deceleration Times (DT) of the E wave, and finally peak A velocity increased (atrial contraction during late diastole) have been shown on echocardiography. (Merli, et al, 2013)

Ascites also affects diastolic dysfunction where reduced E/A ratio (echocardiographic evidence of dysfunction of diastole) have
been found. Alternatively, other parameters of diastolic dysfunction like prolong IVRT and DT remain independent to ascites development. Diastolic dysfunction (normal, pseudonormal and restrictive patterns) is assessed by Doppler echocardiogram where altered E/A ratio indicate diastolic dysfunction. E/A ratio determined by Doppler echocardiography have got limitations for inability to exactly differentiate between pseudo normal versus normal filling pattern. (Naqvi, et al, 2017)

Tissue Doppler Imaging (TDI) is a latest technique where tissue velocity of mitral annulus (e’) at the basal and septal angle is assessed which is considered more sensitive indicator of diastolic dysfunction. Diastolic dysfunctions are considered when lateral e’ < 10 cm/s, septal e’ < 8 cm/s, mitral inflow patterns and LA volume index ≥ 34 mL/m (Figure 4). (Ruiz-del-Arbol & Serradilla, 2015)

Figure (4) Algorithm for the diagnosis of cirrhotic cardiomyopathy. (Ruiz-del-Arbol & Serradilla, 2015)
Cirrhotic cardiomyopathy

Severity and correlation:

Severity of diastolic dysfunction is usually classified according to average E/e' ratio from mild grade 1 to severe grade 3. Most cirrhotics have mild grade 1 or moderate grade II diastolic dysfunction. Diastolic dysfunctions have been well correlated with severity of liver disease and high MELD score. Ruiz-del-Arbol et al. have shown an association of diastolic dysfunction severity and derangement of systolic indices at rest in patients with CCM. Karagiannakis et al. showed correlation between E/e' ratio (diastolic dysfunction) and serum bacterial endotoxin marker (lipopolysaccharide-binding protein). (Karagiannakis, et al, 2013)

Electrophysiological aberration

Cirrhosis of liver brackets together various electrophysiological irregularities including electromechanical uncoupling, prolongation of QT interval, and chronotropic ineffectiveness. (Moller S & Bernardi M, 2013)

Prolongation of QT interval:

Prolong QT interval (>0.44 S) has been observed with portal hypertension with and without cirrhosis. Its frequency among cirrhotics is about 30-60% correlated to the worsening of liver disease. Ventricular repolarization responsible for QT interval varies in its duration to even the slightest change in portal pressure among cirrhotics. Loss of K channel on plasma membrane and their dysfunctions are responsible for delayed ventricular repolarization eventually leading to prolong QT interval. (Mozos, 2015)

Lengthen QT interval is also elucidated by the hyperactivity of sympathoadrenergic discharge as evidenced by high circulating levels of noradrenalin. Autonomic dysfunction along with exposure of different cytokines through portosystemic shunts to heart are also proposed mechanism for prolong QT interval. It is worth noting that patients undergoing liver transplantation are found to have prolonged QTc interval (≥ 500 ms). QTc gets corrected after
transplantation in about 50% of the patients. Chronic β-blocker administration has shown reduction in prolong QT interval. Patients with prolong QT interval may have ventricular arrhythmias. (Ruiz-del-Arbol & Serradilla, 2015)

**Electromechanical uncoupling:**

The dyssynchronous contractile response of systole to electrical signals is termed as electromechanical uncoupling. Electromechanical dyssynchrony has two components, preejection phase (time interval between ventricular depolarization and ventricular ejection) and LV ejection phase. Extended preejection time delay and electromechanical delay have been reported among cirrhotics both at rest and after isometric exercise, thus suggested electromechanical dyssynchrony. Decrease concentration of L-type calcium channels are associated with defective excitation contraction coupling in animal models. Cirrhotics with prolonged QT interval have more chances of electromechanical uncoupling. Dysfunctional K channels are associated with impaired excitation contraction coupling. (Pall, et al, 2014)

**Chronotropic and inotropic incompetence:**

Incapability of heart to proportionally increase its rate in response to metabolic challenges is known chronotropic incompetence. Chronotropic response to dobutamine remains normal in early cirrhosis. Chronotropic incompetence is observed in advance cirrhosis irrespective to underlying aetiology. Cirrhotics have revealed chronotropic incompetence in response to exercise, pharmacologic stimuli, paracentesis and infections. Reduced sensitivity of activation in Sympathetic Nervous System (SNS) due to down regulation and desensitization to beta adrenergic receptors in sinoatrial node is the proposed mechanism for chronotropic incompetence. (Dahl, et al, 2014)
Autonomic dysfunction

Autonomic dysfunction related to cardiovascular system frequently observed in decompensated cirrhosis with a reported incidence of autonomic neuropathy of 35% to 80%. Autonomic dysfunction is related to the stage of cirrhosis. Heart rate variability, impaired sensitivity of baroreflex is well described autonomic dysfunctions. Augmented Sympathetic tone in cirrhotic patients leads to excessive interaction of catecholamine (noradrenalin) which causes myocardial damage and down regulation of β-adrenergic receptor. (Frith & Newton.,2009)

β-Adrenergic receptors dysfunction:

Myocardial contractility is strictly modulated by the β adrenoceptors system. β adrenoceptors system is activated by catecholamine’s (adrenaline and noradrenalin) which are coupled with GS protein and causes an ultimate discharge of cAMP. The Gs protein system is also responsible for direct opening of ca channel on scarcolemma. cAMP is a well known second essenger which activates its dependent Protein Kinase (PKA).Activated protein kinase phosphorylates L-type Ca channel protein,tropopnin and ryanodine receptor which ultimately increases influx of calcium within myofibrils and causes contraction. ( Ruiz-del-Arbol & Serradilla,2015)

Experimental cirrhosis (cirrhotic rats) have shown impaired β adrenergic signal on cardiomyocyte. Several molecular derangements such as decrease density, desensitization, defective production of cAMP and adenylyl cyclase of β adrenergic receptors have been discovered in cirrhotic rats. Down regulation of β adrenergic receptors were found on lymphocytes of decompensated cirrhotic patient which was correlated with cardiac contractility. (Naqvi,et al,2017)
Altered cardiomyocyte membrane:

Cardiomyocyte membrane fluidity changes due to alteration in the composition of plasma membrane both in animal models and human cirrhotic patients. Increase in plasma membrane cholesterol of cirrhotic patients lead to decrease fluidity and made erythrocytes rigid and impermeable. These chemical changes in cardiomyocyte membrane impede with activation of β adrenoceptors system and calcium channels. In the cirrhotic rat model reduced plasma membrane fluidity with abnormally expressed gene at the post receptor level of the adrenergic system causes impaired second messenger (cAMP) signaling on infusion of isoproterenol. (Ceolotto, et al, 2008)

Modified membrane fluidity hampers stimulation of cardiac muscarinic receptors responsible of pacemaker activity. Experimental cirrhosis has also shown defective responsiveness to muscarinic receptors. Altered membrane cholesterol also causes modified activity of sarcoplemma enzymes like Na+/Ca++ exchanger; ATPase and calcium pump ATPase leading to electrocardiograph changes. (Naqvi, et al, 2017)

Cardiac inhibitory factors

Following humoral factors with cardiosuppressant effect in experimental cirrhosis are;

Endocannabinoid (ECS):

These are a group of molecules used for lipid signaling [86]. The ECS system (arachidonoyl ethanolamine and 2-arachidonoylglycerol) are found to be elevated in cirrhosis causing decrease intracellular cytosolic calcium concentration by inhibiting L type Ca++ channels on cardiomyocyte. Reduced cardiac contractile response to isoproterenol has been evidenced in the fibrocholestatic heart model. (Mallat, et al, 2013)
Nitric oxide (NO):

Excessive production of NO secondarily to enzyme inducible Nitric Oxide synthase (iNO) with a negative inotropic effect is reported in experimental studies. BDL rat model has shown decrease cardiac contractility due to high level of iNO which is confirmed upon its reversal with administration of NOS inhibitor L-NMMA (N omegamonomethyl-l arginine) and L-NAME (NGL-nitro-arginine methyl ester) Experimental evidence further suggested that increase activity of NO is related to different cytokines among cirrhotic animals. Effect of nitration of NO on cardiomyocyte has also been linked to CCM (Seddon, et al, 2007)

Carbon monoxide (CMO):

CMO is a degradation product of haem which is catalyzed by enzyme Haem Oxygenase (HO). Endotoxemia, release of cytokines among cirrhotics stimulate HO which causes more production of CMO. Experimental cirrhotic model has shown unregulated activity of HO in the ventricles of BDL cirrhotic rats when compared to sham control rats. Elevated level of CMO reduces cardiac contractility as evidenced by improvement in cardiac contraction after administration of zinc protoporphyrin which is an antagonist of CMO. (Mani, et al, 2006)

BDL cirrhotic rats have shown increase level of cyclic guanosine monophosphate cGMP in response to activation of the NO and CMO with their synthetic enzymes. CGMP either by phosphorylation of G kinase protein or by reducing production of raynodule receptor ultimately causes decrease intra cellular calcium with cardiomyocytes. (Naqvi, et al, 2017)

Programme Cell Death and Cardiac Contractility

Programme cell death contributes in cardiac remodeling after heart failure. An impaired Na+/Ca++ exchanger on membrane of cardiomyocyte among cirrhotics leads to an excessive influx of calcium which initiates apoptosis in cardiomyocytes. Recent
evidence has shown the combined role of cardiosuppressants (CMO, NO, ECS) and apoptosis in CCM. An extrinsic apoptotic pathway has been identified for impaired cardiac contractility in BDL cirrhotic mice. Mitogen-Activated Protein Kinase (MAPKs) with its isoform p38-MAPK has been identified for apoptosis after ischemia in the experimental cirrhosis. (Nam et al, 2014)

**Clinical Features**

CCM clinically remains asymptomatic initially until the physiological or pharmacologic stress has occurred which requires a high cardiac activity to preserve hemodynamic balance. Cardiac incompetence to combat with situations requiring increased cardiac output further increases with advancement of cirrhosis. In the advance stage of cirrhosis cardiac dysfunction and chronotropism become so enunciated that it even fails to increase cardiac output even without any stress conditions. Exercise tolerance decreases with left ventricular diastolic dysfunction. Cardiac failure remains silent due to marked peripheral vasodilatation in cirrhosis. Overt heart failure and extensive pulmonary edema is reported in cirrhotic patients after TIPS and orthotopic liver transplantation. (Bernardi, 2013)

**Hepatorenal Syndrome (HRS)**

CCM has been linked to the pathogenesis of HRS as it causes changes in effective circulatory volume, and considered as a sensitive indicator for development of HRS. (Naqvi et al, 2017)

Several studies have showed a clear association between abnormal LVSF and renal failure. A longitudinal study performed in a large cohort of patients with cirrhosis and tense ascites with normal renal function at baseline, strongly supports the assumption that CCM contributes to the pathogenesis of hepatorenal syndrome (HRS). (Ruiz-del-Arbol et al, 2013)

These patients were studied at inclusion and following the development of HRS. Forty percent of patients developed HRS.
Patients who went on to develop HRS had significantly lower baseline mean arterial pressure, CO, stroke volume (SV), left-ventricular stroke work (LVSW) and significantly higher PRA and norepinephrine concentration when compared with those who did not develop HRS. after developing HRS, patients experienced a further increase in the activity of vasoconstrictor hormones and a further deterioration of their hemodynamics with a decrease in their mean arterial pressure, CO, SV, and LVSW. baseline PRA and CO were the only independent predictors for the development of HRS. Non-azotemic patients with more advanced stage of CCM could be specially predisposed to develop HRS. (Ruiz-del-Arbol, et al., 2013)

Krag et al have demonstrated a significant relationship between the degree of systolic and renal dysfunction in patients with decompensated cirrhosis. On the other hand, in a different study we have recorded systemic hemodynamics and endogenous vasoactive systems in patients with spontaneous bacterial peritonitis (SBP) at the time of diagnosis and following infection resolution. patients developing HRS after SBP resolution showed a reduction of 32% in CO whereas these changes were not observed in patients who did not develop HRS. SVR values were normal or reduced and the HR did not increase despite an intense stimulation of the endogenous vasoconstrictor systems. (Krag, et al., 2010)

Circulatory dysfunction in type-1 HRS, therefore, appeared to be related to the simultaneous occurrence of a progression of arterial vasodilation and a decrease in CO. the results of these studies suggest that LVSF is insufficient to maintain adequate arterial blood pressure and renal perfusion and plays an important role in the pathogenesis of HRS. (Ruiz-del-Arbol L, et al., 2013)

**Sepsis and SBP**

Heart failure becomes evident in the case of sepsis due to decrease cardiac output and hypotension. The high level of inflammatory cytokines generates metabolic stress, which is responsible for circulatory failure. (Moller & Bendtsen, 2015)
Sudden death

Patients with cirrhosis of liver may have sudden cardiac death which has been reported as a clinical implication of CCM. It is associated with QT interval prolongation which has been associated with ventricular arrhythmias. (Bernardi, 2013)

Diagnosis of CCM

Diagnostic criteria for CCM were proposed by an expert panel in 2005 at the World Congress of Gastroenterology in Montreal (Table 1) which includes systolic, diastolic and electrophysiological components as given in (Table 4). Ruiz-del-Arbol et al. has recently proposed a useful diagnostic algorithm for CCM. (Ruiz-del-Arbol & Serradilla, 2015)

Table (4): The 2005 WGO cirrhotic cardiomyopathy criteria. (Gassanov, et al., 2014)

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic dysfunction: blunted increase in CO with exercise, volume challenge or pharmacological stimuli; resting LVEF &lt;55%</td>
</tr>
<tr>
<td>Diastolic dysfunction: prolonged deceleration time (&gt;200 ms); prolonged isovolumetric relaxation time (&gt;80 ms); E:A ratio &lt;1</td>
</tr>
<tr>
<td>Supportive criteria: electrophysiological abnormalities; abnormal chronotropic response; electromechanical uncoupling; prolonged QTc interval; enlarged left atrium; increased myocardial mass; increased BNP and proBNP levels; increased troponin I levels</td>
</tr>
</tbody>
</table>

Laboratory Findings

Cardiac biomarkers

The elevation of Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP) as biomarkers have been found as an
indicator of compromised myocardial contractility and impaired diastole among cirrhotics. ANP and BNP were included as supportive criteria of CCM. (Naqvi, et al, 2017)

**Atrial natriuretic peptide:**

This peptide is primarily secreted by atrial stretch due to volume overload and left ventricular hypertrophy in the cirrhotics. Echocardiographically enlarged atrium is an indirect evidence of high filling pressure. The raised level of ANP was found in cirrhotic patients with ascites. (Rahman & Mallett, 2015)

**B-type natriuretic peptide:**

BNP with its prohormone NTproBNP is produced by the ventricles secondary to ischemia and ventricular pressure or volume overload. Secretion of NT-Prohormone in ventricular overload counteracts Renin Angiotensin Aldosterone (RAAS) by natriuresis and water elimination. (Licata, et al, 2013)

Raised level of BNP and NT-pro BNP were found to be correlated with advanced cirrhosis, LV septal thickness, LV diameter in diastole, HR and QT interval. Raised level of BNP and NT-proBNP are correlated with end diastolic pressure (diastolic stretch). BNP and NT-proBNP have shown a well correlation with PCWP and E/e’ ratios in cirrhotics even with normal LV function. BNP is considered as an early marker of CCM. NT-proBNP level >290pg/ml in a cirrhotic patient requires further cardiac evaluation. (Ruiz-del-Arbol, et al, 2013)

**Cardiac troponin:**

Troponins structural proteins are specific indicators of myocardial injury. Patients with alcoholic cirrhosis have shown elevated troponin I with an association to decrease cardiac output and ventricular mass without having any correlation to severity of cirrhosis. Conversely troponin c levels well correlated with severity and mortality. (Wiese, et al, 2014)
Adrenomedullin:

Adrenomedullin hormone synthesized by cardiac tissue regulates natriuresis and vascular tone. Its level is raised in cirrhotics both with and without CCM. Adrenomedullin is related to inotropism by activating cAMP which increases production of NO. (Welsh et al, 2016)

Novel cardiac biomarker:

Galectin and copeptin are newly investigated cardiac biomarker in cardiovascular disease. Galectin-3 level is found to be high in cirrhotics and been linked to myocardial fibrosis. (Farr M & Schulze, 2015)

Echocardiography

Echocardiography is a noninvasive diagnostic modality for CCM. It is a screening tool for patients with liver cirrhosis. Earlier studies have shown various echocardiographic features as discussed earlier. Cardiac doppler echocardiography: Diastolic dysfunction due to underlying ventricular relaxation delay is suggested by decrease and/or reversal of E/A ratio <1 prolonged E wave deceleration time and isovolumetric relaxation time. Echocardiographic assessment of Global Longitudinal Strains (GLS) has shown an effective parameter for detecting systolic and diastolic dysfunction. (Pall, et al, 2014)

Tissue doppler imaging:

This is a more precise modality for detection of early diastolic mitral annulus velocity (e’) which is considered specific for diastolic dysfunction. The criteria laid down by the American society of Echocardiography have been discussed earlier. Left atrial dysfunction can be assessed by speckle tracking. (Naqvi, et al, 2017)

ECG (Electrocardiogram)

Electrographic abnormalities in CCM including prolonged QT interval, atrial and ventricular premature contractions, bundle branch
Cirrhotic cardiomyopathy

block and electromechanical dissociation have been discussed earlier. (Naqvi, et al, 2017)

**Cardiac scintigraphy**

There is limited data available on cardiac Scintigraphy in evaluation of CCM. Small increase in EF (a predictor of systole) after physiological stress can be revealed by Scintigraphy in cirrhotics when compared to non cirrhotic patients. (Naqvi, et al, 2017)

**Magnetic Resonance Imaging (MRI)**

Cardiac MRI is considered as a gold standard for accurate assessment of morphology of heart. It exactly defines the endocardial and pericardial borders. MRI with gadolinium contrast may determine EF, various volumes of cardiac chambers, myocardial fibrosis and edema. MRI in cirrhotics have shown increase volume of left atrium, left ventricular hypertrophy and raised left ventricular volume at the end of diastole. (Pall, et al, 2014)

**Management of CCM**

To date there is no specific treatment available for CCM. CCM is treated like heart failure due to any other aetiology where sodium and water restriction, beta-blocker, diuretics and RAAS inhibitors are used. Maintenance of sinus rhythm is mandatory as atrial fibrillation increases dyspnea and aggravates ascites in patients with cirrhosis. (Naqvi, et al, 2017)

**β-blockers**

Non selective agents (nodalol, propranalol) have shown a reduction in prolongation of QT interval. Nitrates association with β blocker has shown more reduction in preload, an important target for treatment of diastolic dysfunction. Animal cirrhotic models have shown impairment of early diastole by β blockers. (Ruiz-del-Arbol & Serradilla, 2015)
Cirrhotic cardiomyopathy

Diuretics

Diuretics reduce preload in CCM with heart failure as they benefit in fluid retention, but their long term use may provoke electrolytes disturbance, hypovolemia and even HRS. Diuretics should be used cautiously in cirrhotic patients. (Naqvi, et al., 2017)

Cardiac glycosides and inotrops

Patients with CCM have shown down regulation of β-adrenoceptors inotrops like dobutamine and isoproterenol fails to improve diastolic dysfunction. Digitalis has also shown no improvement in systolic functions of patients with alcoholic cirrhosis as it can be dangerous It is not recommended for treatment of CCM. (Naqvi, et al., 2017)

Angiotensin Converting Enzyme Inhibitors (ACEI)

ACEI improves diastolic functions in cirrhotic patients by decreasing ventricular thickness and dilatation and only be used in early cirrhosis (Child A). Major concerns with these drugs are hypotension and HRS. Currently there is no definite data available about use of ACEI in CCM. (Bos, et al., 2005)

Angiotensin-II receptor blockers

ACEI have not shown any clinical benefit in patients with cirrhosis. Aldosterone antagonists have also shown reduction in ventricular wall thickness and end diastolic volume in early cirrhosis. (Vizzardi, et al., 2010)

Steroids

Patients with CCM also have adrenal insufficiency which further compromises cardiac contractility. Earlier studies have demonstrated some improvement of cardiac function in this stress (hypoadrenalism) in CCM patients. (Theocharidou, et al., 2012)
Liver transplantation

Liver transplantation is as an effective treatment modality of cirrhosis and CCM which has demonstrated improvement in cardiac dysfunction. Post transplant patients after 12 months have shown improvement in both diastolic and systolic function. Financial concerns, lack of availability, limited organ donors and the procedural risks like heart failure, myocardial infarction, tachyarrhythmia and cardiac death are major constraints of liver transplantation. (Naqvi, et al, 2017)